Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

被引：4

作者：

Broeckelmann, Paul J. ^{[1
,2
]}

Pluetschow, Annette ^{[1
,2
]}

Greil, Richard ^{[3
,4
,5
]}

Zijlstra, Josee M. ^{[6
]}

Illidge, Timothy ^{[7
]}

Fossa, Alexander ^{[8
,9
]}

Meissner, Julia ^{[10
,11
]}

Zimmermann, Andreas ^{[12
]}

Mathas, Stephan ^{[13
]}

Thol, Felicitas ^{[14
]}

Fuchs, Michael ^{[1
,2
]}

Engert, Andreas ^{[1
,2
]}

Baues, Christian ^{[15
,16
]}

机构：

[1] Univ Cologne, German Hodgkin Study Grp, Cologne, Germany

[2] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Dusseldo, Cologne, Germany

[3] Paracelsus Med Univ, Med Dept Hematol 3, Med Oncol Rheumatol & Infectiol, Salzburg, Austria

[4] Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials, Salzburg, Austria

[5] Canc Cluster Salzburg, Salzburg, Austria

[6] Vrije Univ Amsterdam, Dept Hematol, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands

[7] Univ Manchester, Manchester Acad Hlth Sci, Natl Inst Hlth & Res,Biomed Res Ctr,Fac Biol Med, Christie Hosp Natl Hlth Serv Fdn Trust,Div Canc S, Manchester, Lancs, England

[8] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[9] Oslo Univ Hosp, Oslo, Norway

[10] Heidelberg Univ, Med 5, Heidelberg, Germany

[11] Univ Heidelberg Hosp, Dept Internal Med 5, Heidelberg, Germany

[12] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Dept Hematol Oncol, Munich, Germany

[13] Charite Univ Med Berlin, Hematol Oncol & Tumor Immunol, Berlin, Germany

[14] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, NH, Germany

[15] Univ Hosp Cologne, Fac Med, Dept Radiooncol & Cyberknife Ctr, Cologne, Germany

[16] Univ Hosp Cologne, Cologne, Germany

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124351

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1547

引用

页数：4

共 50 条

[1] A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Song, Yuqin
Wu, Jianqiu
Chen, Xinchuan
Lin, Tongyu
Cao, Junning
Liu, Yanyan
Zhao, Yaozhong
Jin, Jie
Huang, Haiwen
Hu, Jianda
Luo, Jun
Zhang, Liling
Xue, Hongwei
Zhang, Qingyuan
Wang, Weiwei
Chen, Chunxia
Feng, Jifeng
Zhu, Jun
CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7363 - 7369
[2] Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)
Song, Yuqin
Zhou, Keshu
Jin, Chuan
Qian, Zhengzi
Hou, Ming
Fan, Lei
Li, Fei
Ding, Kaiyang
Zhou, Hui
Li, Xiaoling
Chen, Bing
Sun, Xiuhua
Song, Xianmin
Jiang, Ming
Zhang, Qingyuan
Liu, Lihong
Yu, Guohua
Hu, Yu
Zhao, Zheng
Liu, Ligen
Xue, Hongwei
Luo, Jun
He, Bai
Jin, Xiaoping
Zhao, Min
Li, Baiyong
Xia, Yu
Zhu, Jun
FRONTIERS IN ONCOLOGY, 2022, 12
[3] A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Ramchandren, Radhakrishnan
Phillips, Tycel J.
Devata, Sumana
Gabali, Ali M.
Houde, Christiane
Pregja, Silva
Aghamohammadi, Golbon
Wesson, Emily
Hutto, Tony
Fanale, Michelle A.
BLOOD, 2017, 130
[4] Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
Maruyama, Dai
Hatake, Kiyohiko
Kinoshita, Tomohiro
Fukuhara, Noriko
Choi, Ilseung
Taniwaki, Masafumi
Ando, Kiyoshi
Terui, Yasuhito
Higuchi, Yusuke
Onishi, Yasushi
Abe, Yasunobu
Kobayashi, Tsutomu
Shirasugi, Yukari
Tobinai, Kensei
CANCER SCIENCE, 2017, 108 (05) : 1007 - 1012
[5] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
Johnston, Patrick B.
Pinter-Brown, Lauren
Rogerio, Jaqueline
Warsi, Ghulam
Chau, Quincy
Ramchandren, Radhakrishnan
BLOOD, 2012, 120 (21)
[6] Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial
Ding, Kaiyang
Liu, Hailing
Yang, Haiyan
Cao, Lei
Zhao, Xiaoli
Wu, Wei
Zhang, Xiaoyan
Wang, Li
Xu, Wei
Zhu, Huayuan
Li, Jianyong
Fan, Lei
BLOOD, 2021, 138
[7] Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study
Lin, Ningjing
Zhang, Mingzhi
Bai, Hai
Liu, Hui
Cui, Jie
Ke, Xiaoyan
Zhang, Huilai
Liu, Lihong
Yan, Dongmei
Jiang, Yongsheng
Zang, Aimin
Qi, Junyuan
Wang, Li
Liu, Zhuogang
Xu, Bing
Zhang, Ying
Zhang, Zhihui
Zhao, Xielan
Hu, Chunhong
Yang, Shenmiao
Zhou, Hui
Shi, Jinsheng
Shao, Zonghong
Xiang, Ying
Zhu, Jiman
Song, Yuqin
Zhu, Jun
EUROPEAN JOURNAL OF CANCER, 2022, 164 : 117 - 126
[8] Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial
Jo, Jae-Cheol
Baek, Jin Ho
Lee, Je-Hwan
Joo, Young-Don
Bae, Sung-Hwa
Lee, Jung-Lim
Lee, Jung-Hee
Kim, Dae-Young
Lee, Won-Sik
Ryoo, Hun Mo
Choi, Yunsuk
Kim, Hawk
Lee, Kyoo-Hyung
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (02) : 159 - 166
[9] Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial
O'Connor, Owen A.
Lue, Jennifer K.
Sawas, Ahmed
Amengual, Jennifer E.
Deng, Changchun
Kalac, Matko
Falchi, Lorenzo
Marchi, Enrica
Turenne, Ithamar
Lichtenstein, Renee
Rojas, Celeste
Francescone, Mark
Schwartz, Lawrence
Cheng, Bin
Savage, Kerry J.
Villa, Diego
Crump, Michael
Prica, Anca
Kukreti, Vishal
Cremers, Serge
Connors, Joseph M.
Kurvuilla, John
LANCET ONCOLOGY, 2018, 19 (02): : 257 - 266
[10] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Johnston, Patrick B.
Pinter-Brown, Lauren
Rogerio, Jaqueline
Warsi, Ghulam
Graham, Anne
Ramchandren, Radhakrishnan
BLOOD, 2011, 118 (21) : 1169 - 1169

← 1 2 3 4 5 →